-
7ACC2: MCT1 Inhibitor for Cancer Metabolism
2026-09-17
7ACC2 enables controlled interrogation of lactate uptake, mitochondrial pyruvate handling, and metabolic stress in tumor models. Its nanomolar activity and reported radiosensitizing profile make it useful for cancer metabolism research, while the 25-hydroxycholesterol–macrophage findings suggest a carefully bounded route into immunometabolic assay design.
-
Hoechst 33342/PI Double Staining Kit Workflow
2026-09-17
Use the Hoechst 33342/PI Double Staining Kit to distinguish chromatin condensation from loss of membrane integrity in drug-treated cells. This practical workflow adapts the syringin–sunitinib renal cell carcinoma study into a rapid fluorescent apoptosis assay with clear controls, imaging guidance, and troubleshooting steps.
-
D-Lin-MC3-DMA for Reliable RNA Assays
2026-09-16
Learn how D-Lin-MC3-DMA (SKU A8791) can improve the interpretation of cell viability, proliferation, and cytotoxicity assays used to evaluate siRNA and mRNA delivery. This scenario-based guide connects ionizable lipid chemistry, formulation parameters, controls, storage, and literature-backed LNP performance.
-
Hippo Signaling in Hepatobiliary Maturation
2026-09-16
This preprint identifies HPO1 and HPO2 as spatiotemporally distinct Hippo pathway modules that coordinate hepatocyte and cholangiocyte maturation in mouse liver. Its findings reposition Hippo signaling from a general organ-size regulator to a set of developmental checkpoints that control cell identity, maturation, and survival.
-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-09-15
A 2024 study identifies CLK2 as a mechanistic driver of platinum resistance in ovarian cancer, linking CLK2-dependent BRCA1 Ser1423 phosphorylation to enhanced DNA damage repair. Its tissue, cellular, and xenograft evidence supports CLK2 as a candidate therapeutic target while also defining important limits for translating family-level kinase inhibition into CLK2-specific conclusions.
-
IDH2, Ferroptosis, and TNBC Proliferation
2026-09-15
A 2024 Scientific Reports study identifies wild-type IDH2 as a ferroptosis-associated regulator of triple-negative breast cancer proliferation. By combining tumor-data analysis, clinical validation, cell experiments, and mouse models, the authors connect elevated IDH2 with reduced ferroptotic susceptibility and more aggressive tumor behavior.
-
RapaLink-1: Reframing mTOR Inhibition for Translation
2026-09-14
RapaLink-1, a third-generation mTOR inhibitor, illustrates how bivalent pathway engagement can address resistance while creating a stronger framework for translational research. By connecting oncology data with emerging mTOR-based embryonic dormancy protocols, this article outlines practical validation strategies, experimental parameters, and the limitations that should guide future work.
-
Netarsudil: From ROCK Inhibitor to RNA Assay Design
2026-09-14
Netarsudil (AR-13324) is more than a selective ROCK inhibitor: it is a useful model for connecting trabecular meshwork biology with rational siRNA formulation. This guide explains how to separate direct cytoskeletal effects from nanoparticle-enabled gene silencing in rigorous assay design.
-
Troglitazone as a PPARγ Agonist in TAM Assays
2026-09-13
Troglitazone provides a practical way to test how PPAR-driven metabolic signaling influences macrophage state, SPP1 biology, and tumor-cell responses. This workflow separates established receptor pharmacology from the emerging tumor-associated macrophage opportunity identified by phenotypic screening.
-
M344: A Mechanism-First HDAC Assay Guide
2026-09-12
M344 is a cell-permeable histone deacetylase inhibitor for linking chromatin modulation to proliferation, differentiation, radiation response, and viral latency. This mechanism-first guide explains how to select endpoints, interpret dose responses, and avoid overstating what cell-based assays can establish.
-
Protease Inhibitor Cocktail for RA Signaling Studies
2026-09-11
Learn how a Protease Inhibitor Cocktail can improve protein degradation prevention in rheumatoid arthritis signaling assays. This article connects protease control with STAT1–C3–TNFα crosstalk, assay selection, EDTA compatibility, and reproducible protein analysis.
-
Ceftolozane/Tazobactam: Evidence and Clinical Meaning
2026-09-11
This review examines how ceftolozane/tazobactam combines a PBP-focused cephalosporin with tazobactam to address important resistant gram-negative pathogens, particularly Pseudomonas aeruginosa and selected ESBL-producing Enterobacteriaceae. Its value lies in integrating mechanism, resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, and safety into a framework for interpreting an emerging antibacterial combination.
-
Minoxidil sulphate: Reliable Assay Workflows
2026-09-10
Learn how Minoxidil sulphate (SKU C6513) can support controlled cell, vascular, and hair biology experiments through documented purity, solvent compatibility, and disciplined stock handling. This scenario-based guide connects practical assay decisions with evidence from renal vascular pharmacology.
-
4-MUG Workflow for Lysosomal Enzyme Assays
2026-09-10
4-Methylumbelliferyl-β-D-Glucopyranoside converts β-glucosidase and β-glucocerebrosidase activity into a sensitive fluorescent signal for kinetic, cell-based, and screening workflows. This practical guide connects assay design with optimized GBA1-mRNA research, emphasizing controls, pH-aware detection, and troubleshooting rather than treating fluorescence as a standalone proof of lysosomal rescue.
-
Indomethacin (A8449): Practical Assay Workflow
2026-09-09
Indomethacin (SKU A8449) is a nonsteroidal anti-inflammatory drug for controlled investigation of cyclooxygenase activity, inflammation-associated signaling, lipid metabolism, and membrane-dependent responses. This guide covers solvent selection, assay controls, storage, and interpretation limits; it should not be used to infer cell potency, therapeutic efficacy, or pathway specificity from enzyme-level product data alone.